Drugmakers’ initial stock offerings, which had been a dependable tradition for years, mostly stopped in 2022. Fewer than two dozen biotech businesses priced initial public offerings (IPOs) last year, a 79% decrease from the total of the prior year and a sign of financial hardship for the industry. Even earlier in their company histories, biotech’s […]

The post 5 Challenges That Will Affect Developing Biotech In 2023 first appeared on World Pharma Today.